Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary
Assay data:632 Active, 195 Activity ≤ 1 µM, 9667 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway
Assay data:1034 Active, 2 Activity ≤ 1 nM, 491 Activity ≤ 1 µM, 9667 Tested
Development of inhibitors for PLD2 (Eurofin Panel Assay Results)
Assay data:1 Active, 1 Tested
SummaryCompounds, ActiveRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Development of inhibitors for Dopamine D4 Receptors: Eurofin Panel Assay Results
MLPCN IRAP Measured in Biochemical System Using Plate Reader - 7016-03_Inhibitor_Dose_DryPowder_Activity_Set3
Assay data:1 Active, 24 Tested
MLPCN IRAP Measured in Biochemical System Using Plate Reader - 7016-03_Inhibitor_Dose_DryPowder_Activity_Set2
Assay data:60 Tested
SummaryRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition potency and selectivity
Assay data:11 Active, 20 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro in mouse brain
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Development of a novel orthosteric Muscarinic 5 (M5) antagonist possessing a hig degree of muscarinic subtype selectivity
Assay data:1 Tested
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP assay to assess in vivo activity
MLPCN IRAP Measured in Biochemical System Using Plate Reader - 7016-03_Inhibitor_Dose_CherryPick_Activity_Set2
Assay data:9 Active, 1 Activity ≤ 1 µM, 151 Tested
MLPCN IRAP Measured in Biochemical System Using Plate Reader - 7016-03_Inhibitor_Dose_CherryPick_Activity
Assay data:61 Active, 40 Activity ≤ 1 µM, 151 Tested
ML352 Eurofin Panel Assay for Choline Transporter Inhibitor (Probe Compound)
Development of the first CNS penetrant Muscarinic 5 (M5) Positive Allosteric Modulator based on a novel non-isatin core
Discovery and characterization of a small molecule allosteric agonists of mas-related G-Protein coupled receptor X1 ( MrgX1)
Development of the First Potent, Selective and CNS penetrant M5 Negative Allosteric Modulator (NAM)
SAR Analysis for the identification of selective inhibitors of the two-pore domain potassium channel TASK1 in Kir2.1 expressing cells: FluxOR Assay CRC
Assay data:100 Tested
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP evaluation of activity in vivo
Assay data:2 Active, 2 Tested
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro
Late-stage results from the probe development effort to identify antagonists of OPRK1: CEREP radiometric-based biochemical counterscreen panel assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on